22 de octubre de 2019
  • Lunes, 21 de Octubre
  • 19 de abril de 2016

    COMUNICADO: Nuevos datos preclínicos muestran que la combinación de lenvatinib con everolimus produce mayor actividad antitumoral qu

    3. Adachi Y, et al. Lenvatinib in Combination with Everolimus Demonstrated Enhanced Antiangiogenesis and Antitumor Activity in Human RCC Xenograft Models. AACR 2016; #3264

    4. Motzer R, et al. Randomized phase 2 three-arm trial of lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma. The Lancet Oncology 2015;16:1473-82. Available at http://www.thelancet.com/journals/lanonc/article/PIIS1470-20...(15)00290-9/abstract . Last accessed: March 2016

    5. Okamoto K, et al. Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. ACS Med. Chem. Lett 2015;6:89-94

    6. Wu P. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discovery Today, July 2015;1-6

    7. Cancer Research UK. Available at: http://www.cancerresearchuk.org/about-cancer/cancers-in-gene... . Accessed: March 2016

    8. National Cancer Institute at the National Institute of Health. Available at: http://www.cancer.gov/types/kidney/patient/kidney-treatment-... . Accessed: March 2016

    CONTACTO: Consultas de los medios de comunicación: Eisai, Cressida Robson/ Ben Speller, 19 Abr. (0) - 7908 314 155/+44(0) 7908 409416,Cressida_Robson@eisai.net, Ben_Speller@eisai.net, Tonic LifeCommunications, Alex Davies / Callum Haire, +44 (0)7720 496 472 / +44(0)7867 429 637, Alex.Davies@toniclc.com, Callum.Haire@toniclc.com